Table 2. Relationship between HOXB9 expression and various clinicopathological factors in patients with colon adenocarcinoma (n=63).
| Characteristic | Low-expression group | High-expression group | Statistic method | P | ||
|---|---|---|---|---|---|---|
| |
28 |
44.44% |
35 |
55.56% |
|
|
| Sex |
|
|
|
|
χ2 |
0.63 |
| Male |
16 |
25.40% |
18 |
28.57% |
|
|
| Female |
12 |
19.05% |
17 |
26.98% |
|
|
|
Tumour Nodes Metastases category | ||||||
| T1-2 | 1 | 1.59% | 4 | 6.35% | Fisher's exact test | 0.3707 |
| T3-4 | 27 | 26.98% | 31 | 65.08% | ||
| N0 | 16 | 25.40% | 24 | 38.10% | χ2 | 0.5456 |
| N1-2 | 11 | 17.46% | 12 | 19.05% | ||
| M0 | 26 | 41.27% | 35 | 55.56% | χ2 correction for continuity | 0.3768 |
| M1 |
2 |
3.17% |
0 |
0.00% |
|
|
|
American Joint Committee on Cancer | ||||||
| I | 0 | 0.00% | 3 | 4.76% | Fisher's exact test 0.2092 | 0.3294 |
| II | 17 | 26.98% | 20 | 31.75% | ||
| III | 9 | 14.29% | 12 | 19.05% | Kruskal–Walls test 0.1811 | |
| IV |
2 |
3.17% |
0 |
0.00% |
Spearman's correlation coefficient −0.12490 |
|
|
Differentiation | ||||||
| Poorly differentiation | 9 | 14.29% | 4 | 6.35% | Spearman's correlation coefficient 0.26595 | 0.0436* |
| Moderate differentiation | 17 | 26.98% | 20 | 31.75% | Fisher's exact test 0.1432 | |
| Well differentiation | 2 | 3.17% | 6 | 9.52% | Kruskal–Walls test 0.1332 | |
| Tubular like | 8 | 12.70% | 22 | 34.92% | χ2 | 0.0068* |
| Sieve like |
20 |
31.75% |
13 |
20.63% |
|
|
|
Survival status | ||||||
| Alive | 12 | 19.05% | 24 | 38.10% | χ2 | 0.0404* |
| Dead |
16 |
25.40% |
11 |
17.46% |
|
|
| *Significant P-value, P⩽0.05 | ||||||
Methods including χ2, Fisher's exact test and Spearman's correlation coefficient were used to analyse the correlation between HOXB9 expression and clinicopathological characteristics of patients with colon adenocarcinoma. AJCC is a classification system developed by the American Joint Committee on Cancer.